Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
Filings by filing date
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 835 Industrial Road , 75 SHOREWAY ROAD, SUITE C SAN CARLOS CA 94070 |
Tel: | N/A |
Website: | https://www.atreca.com |
IR: | See website |
Key People | ||
John A. Orwin President, Chief Executive Officer, Principal Financial Officer, Director | Tito A. Serafini Co-Founder, Director | Rick Ruiz Principal Accounting Officer |
Courtney J. Phillips General Counsel, Corporate Secretary | Philippe Bishop Chief Medical Officer |
Business Overview |
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. |
Financial Overview |
For the nine months ended 30 September 2023, Atreca Inc revenues was not reported. Net loss increased 1% to $76.4M. Higher net loss reflects Biopharmaceutical segment loss increase from $28M to $56.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.97 to -$1.95. |
Employees: | 90 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$73.46M as of Sep 30, 2023 |
Net annual income (TTM): | -$97.76M as of Sep 30, 2023 |
Free cash flow (TTM): | -$65.39M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 45,124,558 as of Feb 22, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |